Elaine Chien, MD, FACOG is a board-certified and licensed OB/GYN physician who brings more than 25 years of clinical and biopharmaceutical industry experience to Antiva, including leadership roles on multidisciplinary teams supporting advancement of early to late-stage clinical programs through approval. Prior to joining Antiva, from 2019 to 2023 she held roles of increasing responsibility at Mirum Pharmaceuticals, ultimately serving as Vice President, Clinical Development and Medical Safety with responsibility for overall strategic and executional oversight of all development programs for the company’s clinical-stage asset as well as global medical safety and pharmacovigilance for all of Mirum’s commercial and clinical stage assets. Over Elaine’s career, she has been a key contributor to several US and EU drug approvals, in women’s health and other indications. At Mirum, she was the medical safety lead on multiple sNDAs, an MAA and a Type II Variation for Livmarli® for the treatment of Alagille Syndrome (ALGS) and Primary Familial Intrahepatic Cholestasis (PFIC). Prior to Mirum, Elaine was the global clinical development lead for the Myfembree® pivotal Phase 3 endometriosis program at Myovant Sciences, and the medical safety lead at Clovis Oncology on the NDA and MAA for Rubraca® for BRCA-positive ovarian cancer. Elaine holds a Bachelor of Arts in Economics and an MD from Northwestern University, completed her OB/GYN residency at the Los Angeles County + University of Southern California medical center, and has been a Diplomate of the American Board of Obstetrics and Gynecology since 2005.

• 

  Chief Medical Officer in Antivabio

  Stopping Cancer Before It Starts